Form 4: Biohaven CEO Vlad Coric Buys $5M in Company Shares

Biohaven Ltd. CEO and Director Vlad Coric acquired 666,666 common shares for approximately $5 million through an underwritten public offering.

Summary

• Vlad Coric, Chief Executive Officer and Director of Biohaven Ltd., acquired a total of 666,666 common shares on November 13, 2025.
• The shares were purchased at a price of $7.50 per share, totaling approximately $4,999,995.
• Of these, 333,333 shares were acquired and are held indirectly by The Vlad Coric Family Trust, bringing its total to 1,195,275 shares.
• Another 333,333 shares were acquired and are held indirectly by The Vladimir Coric Marital Trust, bringing its total to 740,546 shares.
• These acquisitions were part of an underwritten public offering.
• Mr. Coric disclaims beneficial ownership of the shares held by the trusts for Section 16 purposes, as they are for the benefit of his family members, excluding himself.
• His direct beneficial ownership stands at 1,797,148 common shares, which includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 30, 2025.
• Additionally, 109,565 shares are held indirectly through a 401(K) Plan.

Sentiment

Score: 8

Explanation: The significant insider purchase by the CEO indicates strong confidence in the company's future, which is a highly positive signal for investors.

Positives

• The Chief Executive Officer and Director, Vlad Coric, made a significant personal investment of nearly $5 million in company shares, signaling strong confidence in Biohaven's future prospects.
• Insider buying, especially by top management, often indicates a belief that the stock is undervalued or that significant positive developments are anticipated.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider purchase may imply management's positive outlook on future company performance.

Management Comments

• Vlad Coric disclaims beneficial ownership of the securities held by The Vlad Coric Family Trust and The Vladimir Coric Marital Trust for purposes of Section 16 or for any other purpose, noting they are held for the benefit of his family members, excluding himself.

Industry Context

Insider purchases, particularly of this magnitude by a CEO, are generally viewed positively across all industries as a strong signal of confidence in the company's valuation and future prospects, often preceding periods of stock appreciation.

Comparison to Industry Standards

• A significant insider purchase by a CEO, such as this nearly $5 million acquisition, is a strong indicator of management's belief in the company's value, often outperforming the average insider buying activity seen in the biotechnology or pharmaceutical sector.
• While specific comparable companies or projects are not detailed in this filing, such a substantial investment by a key executive typically suggests a more robust internal outlook than what might be inferred from general market sentiment or analyst reports alone.

Related Party Transactions

• The acquisition of shares by Vlad Coric, the CEO and Director, through trusts for his family members, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the CEO's significant share purchase as a positive sign, potentially increasing investor confidence and demand for the stock.
• Employees might interpret the CEO's investment as a positive indicator of the company's stability and growth prospects.

Key Dates

Recommendation

The substantial insider purchase by Biohaven's CEO, Vlad Coric, signals strong conviction in the company's future value and performance. Such a significant investment by a key executive often precedes positive developments or indicates a belief that the stock is currently undervalued, making it a compelling 'strong buy' signal for seasoned investors.

Keywords

Biohaven Ltd., BHVN, Vlad Coric, Insider Buying, Share Acquisition, CEO Purchase, Form 4, Public Offering, Common Shares